Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1 -mutated or IDH2 -mutated solid tumours

1 Jun 2017

Abstract excerpt

Introduction High-grade chondrosarcoma, high-grade glioma and intrahepatic cholangiocarcinoma are aggressive types of cancer with a dismal outcome. This is due to the lack of effective treatment options, emphasising the need for novel therapies. Mutations in the genes IDH1 and IDH2 (isocitrate dehydrogenase 1 and 2) occur in 60% of chondrosarcoma, 80% of WHO grade II–IV glioma and 20% of intrahepatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Colorectal Cancer Treatments and Studies
Share to Metabolism, Diabetes, and Cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28601826
DOI: 10.1136/bmjopen-2016-014961

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1 -mutated or IDH2 -mutated solid tumoursPMID 28601826Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future PerspectivesSemantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

Clinical development of IDH1 inhibitors for cancer therapy.Semantic proximity Read ↗

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.Semantic proximity Read ↗

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.Semantic proximity Read ↗

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity Read ↗

IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future PerspectivesSemantic proximity Read ↗

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma cells to MDM2 inhibitorsSemantic proximity Read ↗

Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Semantic proximity Read ↗

Targeting isocitrate dehydrogenase (IDH) in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.